drugset
drugset / Trial / NCT03336632

Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT

NCT03336632 ↗

Phase 2 Unknown 50 enrolled Sichuan University
NaSingle-groupOpen-labelTreatment

Summary

This study is to explore the efficacy and safety of introduction of chidamide in PTCy based GVHD prophylaxis in patients undergoing allogeneic PBSCT.

Timeline

Start
2019-01-01
Primary completion
2020-12-30
Completion
2021-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 20 mg Oral
Background Cyclophosphamide Other / unclassified 50 mg/kg Intravenous
Background Cyclosporine Peptide 3 mg/kg Intravenous

Indications

acute leukemia myelodysplastic syndrome